Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Bubs Australia Ltd. ( (AU:BUB) ) is now available.
Bubs Australia Ltd. reported significant financial growth for the fiscal year 2025, with a 29% increase in net revenue to $102.5 million and a positive EBITDA of $5.5-$6 million, marking a turnaround from the previous year’s loss. The company also achieved positive operating cash flow and has substantial cash reserves. The US market led growth with a 52% increase in revenue, while China, Australia, and other international markets also showed strong performance. Bubs’ submission to the US FDA for its New Infant Formula is expected to enhance its market presence further.
The most recent analyst rating on (AU:BUB) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Bubs Australia Ltd. stock, see the AU:BUB Stock Forecast page.
More about Bubs Australia Ltd.
Founded in 2006 in Australia, Bubs Australia Ltd. specializes in producing clean nutrition products, including A2 Beta-Casein Protein, Organic Grass-fed, and Easy-Digest Goat Milk Infant Formula, as well as an organic baby food range. The company’s products are available in major supermarkets and pharmacies across Australia and are exported to ten international markets, including China, Southeast Asia, the Middle East, and the USA.
Average Trading Volume: 1,937,958
Technical Sentiment Signal: Hold
Current Market Cap: A$151.8M
See more data about BUB stock on TipRanks’ Stock Analysis page.